search
Back to results

Decolonization to Reduce After-Surgery Events of Surgical Site Infection (DECREASE SSI)

Primary Purpose

Surgical Site Infection

Status
Recruiting
Phase
Phase 4
Locations
United States
Study Type
Interventional
Intervention
4% Chlorhexidine Gluconate
2% Mupirocin
Soap Without Antiseptic Properties (Placebo)
Placebo Nasal Ointment
Sponsored by
University of California, Irvine
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Surgical Site Infection focused on measuring Surgical Site Infection, SSI

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • 18 years of age or older
  • Recent surgery that involves the colon or small bowel using an open (non-laparoscopic) approach within the past 14 days
  • Able to communicate regularly by phone
  • Able to bathe, shower or have this task performed by a caregiver

Exclusion Criteria:

  • Transfer to an acute care hospital
  • Discharged to receive end-of-life hospice measures
  • Discharged more than 14 days after surgery
  • Allergic to mupirocin and/or chlorhexidine
  • Active infection at enrollment
  • Surgical incision not closed at the end of surgery

Sites / Locations

  • University of California, Irvine Medical CenterRecruiting
  • University of California, Davis Medical CenterRecruiting
  • University of California, San Francisco Medical CenterRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Placebo Comparator

Arm Label

Decolonization

Routine Care

Arm Description

Participants randomized into this arm will perform decolonization using topical antiseptic soap (chlorhexidine body wash) and an antibiotic ointment (nasal mupirocin).

Participants randomized into this arm will perform routine care using soap without antiseptic properties (placebo) and placebo nasal ointment.

Outcomes

Primary Outcome Measures

Time to First Post-Discharge Surgical Site Infection

Secondary Outcome Measures

Full Information

First Posted
October 15, 2022
Last Updated
August 9, 2023
Sponsor
University of California, Irvine
Collaborators
University of California, Davis, University of California, San Francisco, University of Massachusetts, Amherst
search

1. Study Identification

Unique Protocol Identification Number
NCT05586776
Brief Title
Decolonization to Reduce After-Surgery Events of Surgical Site Infection
Acronym
DECREASE SSI
Official Title
Decolonization to Reduce After-Surgery Events of Surgical Site Infection
Study Type
Interventional

2. Study Status

Record Verification Date
August 2023
Overall Recruitment Status
Recruiting
Study Start Date
January 17, 2023 (Actual)
Primary Completion Date
December 2027 (Anticipated)
Study Completion Date
December 2028 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of California, Irvine
Collaborators
University of California, Davis, University of California, San Francisco, University of Massachusetts, Amherst

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
Yes
Data Monitoring Committee
No

5. Study Description

Brief Summary
The DECREASE SSI Trial (Decolonization to Reduce After-Surgery Events of Surgical Site Infection) is a two-arm multi-center individual placebo-controlled randomized (2,700 participants randomized 1:1) clinical trial to reduce post-discharge surgical site infection following open colon or small bowel surgery by comparing chlorhexidine bathing plus nasal mupirocin in the 30 days following discharge to soap without antiseptic properties (placebo) and placebo nasal ointment. This trial seeks to enhance the care of the 675,000 patients annually who undergo colon and small bowel surgery by finding simple and efficacious interventions to reduce SSI.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Surgical Site Infection
Keywords
Surgical Site Infection, SSI

7. Study Design

Primary Purpose
Prevention
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
2700 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Decolonization
Arm Type
Active Comparator
Arm Description
Participants randomized into this arm will perform decolonization using topical antiseptic soap (chlorhexidine body wash) and an antibiotic ointment (nasal mupirocin).
Arm Title
Routine Care
Arm Type
Placebo Comparator
Arm Description
Participants randomized into this arm will perform routine care using soap without antiseptic properties (placebo) and placebo nasal ointment.
Intervention Type
Drug
Intervention Name(s)
4% Chlorhexidine Gluconate
Intervention Description
Used for daily showering/bathing for 30 days after hospital discharge.
Intervention Type
Drug
Intervention Name(s)
2% Mupirocin
Intervention Description
Applied to each nostril twice daily for five days for the first two weeks after hospital discharge.
Intervention Type
Drug
Intervention Name(s)
Soap Without Antiseptic Properties (Placebo)
Intervention Description
Used for daily showering/bathing for 30 days after hospital discharge.
Intervention Type
Drug
Intervention Name(s)
Placebo Nasal Ointment
Intervention Description
Applied to each nostril twice daily for five days for the first two weeks after hospital discharge.
Primary Outcome Measure Information:
Title
Time to First Post-Discharge Surgical Site Infection
Time Frame
Within 30 Days of Hospital Discharge

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: 18 years of age or older Recent open (not solely laparoscopic) surgery involving an abdominal incision within the past 14 days. For cesarean section, recruitment restricted to BMI ≥ 40. Able to communicate regularly by phone Able to bathe, shower or have this task performed by a caregiver Exclusion Criteria: Transfer to an acute care hospital Discharged to receive end-of-life hospice measures Discharged more than 14 days after surgery Allergic to mupirocin and/or chlorhexidine Active infection at enrollment* *Refers to Infections requiring systemic antibacterial agents, so viral illness (e.g., COVID, flu) is not an exclusion. Topical antibacterial agents do not count toward exclusion (e.g., topical products for acne) Prophylactic antibacterial agents do not count toward exclusion Surgical incision not closed at discharge
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Susan Huang, MD, MPH
Phone
(949) 824-5073
Email
sshuang@hs.uci.edu
First Name & Middle Initial & Last Name or Official Title & Degree
Raveena Singh, MA
Phone
(949) 824-9285
Email
ravsingh@hs.uci.edu
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Susan Huang, MD, MPH
Organizational Affiliation
University of California, Irvine
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Deborah Yokoe, MD, MPH
Organizational Affiliation
University of California, San Francisco
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
Stuart Cohen, MD
Organizational Affiliation
University of California, Davis
Official's Role
Study Director
Facility Information:
Facility Name
University of California, Irvine Medical Center
City
Orange
State/Province
California
ZIP/Postal Code
92868
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Susan Huang, MD, MPH
Phone
949-824-5073
Email
sshuang@hs.uci.edu
First Name & Middle Initial & Last Name & Degree
Susan Huang, MD, MPH
Facility Name
University of California, Davis Medical Center
City
Sacramento
State/Province
California
ZIP/Postal Code
95817
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Stuart Cohen, MD
Phone
916-734-3741
Email
stcohen@ucdavis.edu
First Name & Middle Initial & Last Name & Degree
Stuart Cohen, MD
Facility Name
University of California, San Francisco Medical Center
City
San Francisco
State/Province
California
ZIP/Postal Code
94143
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Deborah Yokoe, MD, MPH
Phone
415-502-4165
Email
deborah.yokoe@ucsf.edu
First Name & Middle Initial & Last Name & Degree
Deborah Yokoe, MD, MPH

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
A data request form will be provided to any researcher requesting data from the DECREASE SSI trial This data request form will request the hypothesis/goal of the research, the planned use of the data, and the requested data elements (deidentified only). Any data provided will include the stipulation that use is limited to research purposes only. Requests will not be granted for pursuits directly specified in the grant. If the data request overlaps with additional ongoing post-grant pursuits either by this team or another investigative team that requested the data for a given purpose, a discussion will be pursued toward the potential for joint collaboration.
IPD Sharing Time Frame
3 years from publication
IPD Sharing Access Criteria
Pending

Learn more about this trial

Decolonization to Reduce After-Surgery Events of Surgical Site Infection

We'll reach out to this number within 24 hrs